Biotechnology financing dilemmas and the role of special purpose entities

Article Abstract:

Legally independent affiliates of biotech companies, which are called as the special purpose entity (SPE), play an important role in the development of several path breaking drugs and success of the biotech firms. The SPE's may be making a comeback but they have to be restructured in order to meet the needs of the companies as well as the investors, but due to their ability to hasten the growth of a company, investment bankers are planning to restructure SPEs for making them attractive to the biotech sector.\

United States, Special-purpose entities

---

Keeping it real with investors

Article Abstract:

The most enduring myths include biotech entrepreneurs benefit, in the long run, from hyperbole because it fuels the kind of media exposure that whets the appetite of investors. Entrepreneurs attempting to commercialize products using nanotech are accused of overselling nanobiotic even though many biotech veterans agree that this enabling technology might substantially enhance the properties and traits of the materials used in imaging and biosensors to medicines and molecular diagnostics.

New York, Civic and Social Organizations, Social services, not elsewhere classified, Fund Raising Agencies, Fund raising

---

Tapping into foundations

Article Abstract:

The advice, networking opportunities and grants provided by not-for-profit organizations to help upcoming biotech companies to launch promising drug discovery to reach the market is reviewed.

United Kingdom, Science & research, SOCIAL SERVICES, Social Assistance, Religious, Grantmaking, Civic, Professional, and Similar Organizations, Nonprofit Institutions, Social Services & Nonprofit Institutns, Research, Nonprofit organizations

Similar abstracts:

• Abstracts: Consumption, dividends, and the cross section of equity returns. Idiosyncratic consumption risk and the cross section of asset returns
• Abstracts: Asset sales, investment opportunities, and the use of proceeds. Optimal asset location and allocation with taxable and tax-deferred investing
• Abstracts: Breaking the mould. Oxera and the mid-tier. Blurred boundaries
• Abstracts: From the ground up. Going for the access and the analytics
• Abstracts: Animal cloning and the FDA - The risk assessment paradigm under public scrutiny

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.